Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gamida Cell Ltd GMDA will terminate 10% of its staff as part of an effort to extend its cash runway for a planned filing for cell therapy omidubicel with the FDA. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided key program and business updates. Initiating rolling BLA submission for omidubicel. Following the recent receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA), Gamida Cell will initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treat

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

American Battery Technology Company

ConforMIS

Can these penny stocks make gains moving forward? The post Popular Penny Stocks to Know About as January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Know About as January Ends

The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan

The stock price of Gamida Cell Ltd (NASDAQ: GMDA) increased by over 20% during intraday trading today. This is why it happened.

Gamida Cell Stock (GMDA): Why The Price Substantially Went Up Today

Splash Beverage Group

Vivos Therapeutics

Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space. The post Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Phunware Inc

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps

Planning to initiate rolling BLA submission for omidubicel following positive Type B meeting with FDA Full BLA submission on track for first half of 2022 BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA) yesterday, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant.

Gamida Cell Says Planning To Initiate Rolling BLA Submission For Omidubicel; Full BLA Submission On Track For 1H 2022

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, announced that following receipt of positive Type B meeting correspondence from the U.S. Food and Drug Administration (FDA) yesterday, the company plans to initiate a rolling Biologics License Application (BLA) submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. As previous

Gamida Cell Provides Update on Omidubicel BLA Submission

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced eight presentations at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT) being held in Salt Lake City, UT, from February 2-6, 2022. New data and analyses on omidubicel will be presented including an oral presentation by Dr. Mitchell Horwitz of Duke Cancer Institute detailing one-year

Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for GDA-201, the company's lead candidate in its NAM-enabled NK cell therapy pipeline, will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, being held in Atlanta, Georgia. Additionally, for patients who participated in the phase 3 trial of omidubicel, the company will be pre

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, presented clinical updates on omidubicel in two presentations on the first day of the 63rd American Society of Hematology (ASH) Annual Meeting being held in Atlanta, Georgia and virtually December 11-14, 2021. In an oral presentation titled “Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel is Associated with Robust Immune Reconstituti

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

New York, New York--(Newsfile Corp. - November 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Gamida Cell Ltd. ("Gamida" or the "Company") (NASDAQ: GMDA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gamida and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida Cell Ltd. - GMDA

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2021. Net loss for the third quarter of 2021 was $19.6 million, compared to a net loss of $14.8 million for the same period in 2020. As of September 30, 2021, Gamida Cell had total cash and cash equivalents of $120.8 million. During the past quarter,

Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, completed a Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. The FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell's whol

Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced data evaluating the mechanism of action of nicotinamide (NAM)-enabled NK cells, demonstrating enhanced homing, cytotoxicity and tumor reduction by GDA-201, the lead candidate in its NAM-enabled NK cell therapy pipeline. The data will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) taking pla

Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 15, 2021, at 8:00 a.m. ET to review its third quarter 2021 financial results and provide an update on the company. The webcast will be available on the “Investors & Media” section of the Gamida Cell website at www.gamida-cell.com. To p

Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced four presentations at the 63rd American Society of Hematology (ASH) Annual Meeting, which is being held in Atlanta, Georgia or virtually from December 11-14, 2021. New data on omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, will be presented during an oral presentation

Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that Aviad Pato, Ph.D., Head of Immunology Research, presented data on two nicotinamide (NAM)-enabled NK cell therapies, GDA-501 and GDA-301, at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Barcelona, Spain, and virtually November 2-4, 2021. The presentation included data from early-stage studies of GD

Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gamida Cell (GMDA) Moves to Buy: Rationale Behind the Upgrade

Gamida Cell (GMDA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Gamida Cell (GMDA) Is a Great 'Buy the Bottom' Stock Now

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, will be hosting a virtual R&D Day event detailing the company's proprietary NAM-enabled natural killer (NK) cell therapy pipeline today, Tuesday, October 26, at 8:00 a.m. ET. During the event, the company will highlight Gamida Cell's new programs leveraging next-generation, NAM-enabled, genetically modified NK cells in development for solid tum

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that data evaluating the company's NAM-enabled NK cell platform will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) taking place in Washington, DC, and virtually November 10-14, 2021. Details about the SITC poster presentations are as follows: Title: Cytotoxicity of nicotinamide enhanced na

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a virtual event detailing the company's proprietary NAM-enabled natural killer (NK) cell therapy pipeline on Tuesday, October 26, 2021 at 8:00 a.m. ET. During the event, the company will highlight updates on the clinical development of GDA-201, its lead cryopreserved, off-the-shelf cell therapy candidate for

News for Gamida Cell Ltd Stock (GMDA)